Therapeutic potential of neurotrophic factors in neurodegenerative diseases

BioDrugs

Volumn 19, Issue 2, 2005, Pages 97-127

  Levy, Yossef S ^a   Gilgun Sherki, Yossi ^a   Melamed, Eldad ^a   Offen, Daniel ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACIDIC FIBROBLAST GROWTH FACTOR; AMYLOID BETA PROTEIN; ANTITUSSIVE AGENT; BASIC FIBROBLAST GROWTH FACTOR; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 6; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; BRONCHODILATING AGENT; CARDIOTROPHIN 1; CARDIOTROPHIN 1 RECEPTOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; CILIARY NEUROTROPHIC FACTOR; CILIARY NEUROTROPHIC FACTOR RECEPTOR; COPPER ZINC SUPEROXIDE DISMUTASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DOPAMINE 2 RECEPTOR; EPIDERMAL GROWTH FACTOR; EXCITOTOXIN; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; GALANTAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR RECEPTOR ALPHA1; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR RECEPTOR ALPHA2; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR RECEPTOR ALPHA3; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR RECEPTOR ALPHA4; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LEUKEMIA INHIBITORY FACTOR; LEUKEMIA INHIBITORY FACTOR RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; NERVE CELL ADHESION MOLECULE; NERVE GROWTH FACTOR; NEUROTROPHIC FACTOR; NEUROTROPHIN 3; NEUROTROPHIN 3 RECEPTOR; NEUROTROPHIN 4; NEUROTROPHIN 6; NEUROTROPHIN 7; NEURTURIN; ONCOSTATIN M; PERSEPHIN; PHOSPHOLIPASE C GAMMA; PROTEIN P75; PROTEIN RET; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE A; QUINOLINIC ACID; RAF PROTEIN; RAS PROTEIN; RECEPTOR; RECOMBINANT BRAIN DERIVED NEUROTROPHIC FACTOR; RECOMBINANT CILIARY NEUROTROPHIC FACTOR; RECOMBINANT SOMATOMEDIN C; S6 KINASE; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TARGET OF RAPAMYCIN KINASE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG;

AGING; AGITATION; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL TISSUE; ANOREXIA; APHTHOUS STOMATITIS; APPETITE DISORDER; ASTHENIA; BACKACHE; BEHAVIOR DISORDER; BODY WEIGHT DISORDER; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COUGHING; DEGENERATIVE DISEASE; DEPRESSION; DIARRHEA; DRUG DELIVERY SYSTEM; DRUG POTENCY; DYSPNEA; ELECTRIC SHOCK; EMBRYO; FATIGUE; FEVER; GLIA; HALLUCINATION; HEADACHE; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; HYPOTENSION; INFLAMMATION; INJECTION SITE REACTION; INTESTINE DISTENSION; MOUSE; NAUSEA; NERVE CELL NECROSIS; NONHUMAN; OLIGODENDROGLIA; PARESTHESIA; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; RAT; RESPIRATORY TRACT INFLAMMATION; REVIEW; SALIVARY GLAND DISEASE; SENSORY DYSFUNCTION; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SYMPTOMATOLOGY; TECHNOLOGY; VIRUS REACTIVATION; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ANIMALS; HUMANS; META-ANALYSIS; NERVE GROWTH FACTORS; NEURODEGENERATIVE DISEASES;

EID: 17644416779     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200519020-00003     Document Type: Review

References (347)

1. Yuen EC, Howe CL, Li Y, et al. Nerve growth factor and the neurotrophic factor hypothesis. Brain Dev 1996; 18: 362-8
2. Grimes ML, Zhou J, Beattie EC, et al. Endocytosis of activated TrkA: evidence that nerve growth factor induces formation of signaling endosomes. J Neurosci 1996; 16: 7950-64
3. Blesch A, Grill RJ, Tuszynski MH. Neurotrophin gene therapy in CNS models of trauma and degeneration. Prog Brain Res 1998; 117: 473-84
4. Ibanez CF. Emerging themes in structural biology of neurotrophic factors. Trends Neurosci 1998; 21: 438-44
5. Thoenen H, Barde YA, Davies AM, et al. Neurotrophic factors and neuronal death. Ciba Found Symp 1987; 126: 82-95
6. Connor B, Dragunow M. The role of neuronal growth factors in neurodegenerative disorders of the human brain. Brain Res Brain Res Rev 1998; 27: 1-39
7. Barnea A, Roberts J, Croll SD. Continuous exposure to brain-derived neurotrophic factor is required for persistent activation of TrkB receptor, the ERK signaling pathway, and the induction of neuropeptide Y production in cortical cultures. Brain Res 2004; 1020: 106-17
8. Binder DK. The role of BDNF in epilepsy and other diseases of the mature nervous system. Adv Exp Med Biol 2004; 548: 34-56
9. Crowder RJ, Enomoto H, Yang M, et al. Dok-6, a novel p62 Dok family member, promotes Ret-mediated neurite outgrowth. J Biol Chem 2004 Oct; 279 (40): 42072-81
10. Ebadi M, Bashir RM, Heidrick ML, et al. Neurotrophins and their receptors in nerve injury and repair. Neurochem Int 1997; 30 (4-5): 347-74
11. Espejo M, Cutillasl B, Arenasl TE, et al. Increased survival of dopaminergic neurons in striatal grafts of fetal ventral mesencephalic cells exposed to neurotrophin-3 or glial cell line-derived neurotrophic factor. Cell Transplant 2000; 9: 45-53
12. Haque NS, Hlavin ML, Fawcett JW, et al. The neurotrophin NT4/5, but not NT3, enhances the efficacy of nigral grafts in a rat model of Parkinson's disease. Brain Res 1996; 712: 45-52
13. Mendez I, Dagher A, Hong M, et al. Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line-derived neurotrophic factor in patients with Parkinson's disease: report of two cases and technical considerations. J Neurosurg 2000; 92: 863-9
14. Mufson EJ, Kroin JS, Sendera TJ, et al. Distribution and retrograde transport of trophic factors in the central nervous system: functional implications for the treatment of neurodegenerative diseases. Prog Neurobiol 1999; 57: 451-84
15. Gotz R, Koster R, Winkler C, et al. Neurotrophin-6 is a new member of the nerve growth factor family. Nature 1994; 372: 266-9
16. Nilsson AS, Fainzilber M, Falck P, et al. Neurotrophin-7: a novel member of the neurotrophin family from the zebrafish. FEES Lett 1998; 424: 285-90
17. Francke U, de Martinville B, Coussens L, et al. The human gene for the beta subunit of nerve growth factor is located on the proximal short arm of chromosome 1. Science 1983; 222: 1248-51
18. Leibrock J, Lottspeich F, Hohn A, et al. Molecular cloning and expression of brain-derived neurotrophic factor. Nature 1989; 341: 149-52
19. Maisonpierre PC, Le Beau MM, Espinosa R, et al. Human and rat brain-derived neurotrophic factor and neurotrophin-3: gene structures, distributions, and chromosomal localizations. Genomics 1991; 10: 558-68
20. Ernfors P, Ibanez CF, Ebendal T, et al. Molecular cloning and neurotrophic activities of a protein with structural similarities to nerve growth factor: developmental and topographical expression in the brain. Proc Natl Acad Sci U S A 1990; 87: 5454-8
21. Hohn A, Leibrock J, Bailey K, et al. Identification and characterization of a novel member of the nerve growth factor/brain-derived neurotrophic factor family. Nature 1990, 41
22. Hallbook F, Ibanez CF, Persson H. Evolutionary studies of the nerve growth factor family reveal a novel member abundantly expressed in Xenopus ovary. Neuron 1991; 6: 845-58
23. Berkemeier LR, Winslow JW, Kaplan DR, et al. Neurotrophin-5: a novel neurotrophic factor that activates trk and trkB. Neuron 1991; 7: 857-66
24. Berkemeier LR, Ozcelik T, Francke U, et al. Human chromosome 19 contains the neurotrophin-5 gene locus and three related genes that may encode novel acidic neurotrophins. Somat Cell Mol Genet 1992; 18: 233-45
25. Martin-Zanca D, Mitra G, Long LK, et al. Molecular characterization of the human trk oncogene. Cold Spring Harb Symp Quant Biol 1986; 51: 983-92
26. Bothwell M. Keeping track of neurotrophin receptors. Cell 1991; 65: 915-8
27. Glass DJ, Nye SH, Hantzopoulos P, et al. TrkB mediates BDNF/NT-3-dependent survival and proliferation in fibroblasts lacking the low affinity NGF receptor. Cell 1991; 66: 405-13
28. Johnson H, Hokfelt T, Ulfhake B. Decreased expression of TrkB and TrkC mRNAs in spinal motoneurons of aged rats. Eur J Neurosci. 1996; 8: 494-9
29. Cordon-Cardo C, Tapley P, Jing SQ, et al. The trk tyrosine protein kinase mediates the mitogenic properties of nerve growth factor and neurotrophin-3. Cell 1991; 66: 173-83
30. Ip NY, Stitt TN, Tapley P, et al. Similarities and differences in the way neurotrophins interact with the Trk receptors in neuronal and nonneuronal cells. Neuron 1993; 10: 137-49
31. Lee KF, Li E, Huber J, et al. Targeted mutation of the gene encoding the low affinity NGF receptor p75 leads to deficits in the peripheral sensory nervous system. Cell 1992; 69: 737-49
32. von Schack D, Casademunt E, Schweigreiter R, et al. Complete ablation of the neurotrophin receptor p75NTR causes defects both in the nervous and the vascular system. Nat Neurosci 2001; 4: 977-8
33. Bibel M, Barde YA. Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system. Genes Dev 2000; 14: 2919-37
34. Lee R, Kermani P, Teng KK, et al. Regulation of cell survival by secreted proneurotrophins. Science 2001; 294: 1945-8
35. Nykjaer A, Lee R, Teng KK, et al. Sortilin is essential for proNGF-induced neuronal cell death. Nature 2004; 427: 843-8
36. Yamashita T, Higuchi H, Tohyama M. The p75 receptor transduces the signal from myelin-associated glycoprotein to Rho. J Cell Biol 2002; 157: 565-70
37. Mi S, Lee X, Shao Z, et al. LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex. Nat Neurosci 2004; 7: 221-8
38. Aguado F, Majo G, Gomez de Aranda I, et al. Trk neurotrophin receptor family immunoreactivity in rat and human pituitary tissues. Neurosci Lett 1998; 243: 13-6
39. Moga MM, Duong T. P75 neurotrophin receptor immunoreactivity in the aged human hypothalamus. Neurosci Lett 1997; 231: 9-12
40. Allen SJ, Dawbarn D, Spillantini MG, et al. The distribution of β-nerve growth factor receptors in the human basal forebrain. J Comp Neurol 1989; 289: 626-40
41. Dawbarn D, Allen SJ, Semenenko FM. Coexistence of choline acetyltransferase and nerve growth factor receptors in the forebrain of the rat. Neurosci Lett 1988; 94: 138-4
42. Dawbarn D, Allen SJ, Semenenko FM. Immunohistochemical localization of β-nerve growth factor receptors in the forebrain of the rat. Brain Res 1988; 440: 185-9
43. Kordower J, Bartus RT, Bothwell M, et al. Nerve growth factor receptor immunoreactivity in the nonhuman primate Cebus apella: distribution morphology and colocalization with cholinergic enzymes. J Comp Neurol 1988; 277: 465-86
44. Riopelle J, Richardson PM, Verge VM. Distribution and characteristics of nerve growth factor binding on cholinergic neurons of rat and monkey forebrain. Neurochem Res 1987; 12: 923-8
45. Sobreviela T, Clary DO, Reichardt LF, et al. TrkA-immunoreactive profiles in the central nervous system: colocalization with neurons containing p75 nerve growth factor receptor choline acetyltransferase and serotonin. J Comp Neurol 1994; 350: 587-611
46. Steininger TL, Wainer BH, Klein R, et al. High-affinity nerve growth factor receptor Trk immunoreactivity is localized in cholinergic neurons of the basal forebrain and striatum in the adult rat brain. Brain Res 1993; 612: 331-5
47. Chao MV, Bothwell M. Neurotrophins: to cleave or not to cleave. Neuron 2002; 33: 9-12
48. Wang Y, Hagel C, Hamel W, et al. TrkA, B and C are commonly expressed in human astrocytes and astrocytic gliomas but not by human oligodendrocytes and oligodendroglioma. Acta Neuropathol (Berl.) 1998; 96: 357-64
49. Quartu M, Geic M, Del Fiacco M. Neurotrophin-like immunoreactivity in the human trigeminal ganglion. Neuroreport 1997; 8: 3611-7
50. Pearson J, Johnson EM, Brandeis L. Effects of antibodies to nerve growth factor on intrauterine development of derivatives of cranial neural crest and placode in the guinea pig. Dev Biol 1983; 96: 32-6
51. Murer MG, Boissiere F, Yan Q, et al. An immunohistochemical study of the distribution of brain-derived neurotrophic factor in the adult human brain, with particular reference to Alzheimer's disease. Neuroscience 1999; 88: 1015-32
52. Soontornniyomkij V, Wang G, Pittman CA, et al. Expression of brain-derived neurotrophic factor protein in activated microglia of human immunodeficiency virus type I encephalitis. Neuropathol Appl Neurobiol 1998; 24: 453-60
53. Seroogy KB, Lundgren KH, Tran TM, et al. Dopaminergic neurons in rat ventral midbrain express brain-derived neurotrophic factor and neurotrophin-3 mRNAs. J Comp Neurol 1994; 342; 321-34
54. Chauhan NB, Siegel GJ, Lee JM. Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain. J Chem Neuroanat 2001; 21: 277-88
55. Chauhan NB, Lee JM, Siegel GJ. Reductions in glial cell line-derived neurotrophic factor (GDNF) in substantia nigra neurons of Parkinson's disease brain [abstract]. Soc Neurosci Abstr 1998; 24: 1465
56. Chauhan NB, Lee JM, Siegel GJ. Selective depletion of glial cell line-derived neurotrophic factor (GDNF) in Parkinson's disease. Neurology 1999; 52: A212-213
57. Thome J, Nara K, Foley P, et al. Ciliary neurotrophic factor (CNTF) genotypes: influence on choline acetyltransferase (ChAT) and acetylcholine esterase (AchE) activities and neurotrophin 3 (NT3) concentration in human post mortem brain tissues. J Hirnforsch 1997; 38: 443-51
58. Landreth GE. Growth factors. In: Siegel GJ, Agranoff BW, Albers RW, et al., editors. Basic neurochemistry, molecular, cellular and medical aspects. 6th ed. Philadelphia (PA): Lippincott-Raven, 1999: 384-96
59. Crowley C, Spencer SD, Nishimura MC, et al. Mice lacking nerve growth factor display perinatal loss of sensory and sympathetic neurons yet develop basal forebrain cholinergic neurons. Cell 1994; 76: 1001-11
60. Jones KR, Farinas I, Backus C, et al. Targeted disruption of the BDNF gene perturbs brain and sensory neuron development but not motor neuron development Cell 1994; 76: 989-99
61. Quartu M, Lai ML, Del Fiacco M. Neurotrophin-like immunoreactivity in the human hippocampal formation. Brain Res Bull 1999; 48: 375-82
62. Massague J, Blain SW, Lo RS. TGF beta signaling in growth control, cancer, and heritable disorders. Cell 2000; 103: 295-309
63. Dennler S, Goumans MJ, ten Dijke P. Transforming growth factor beta signal transaction. J Leukoc Biol 2002; 71: 731-40
64. Poulsen KT, Armanini MP, Klein RD, et al. TGF beta 2 and TGF beta 3 are potent survival factors for midbrain dopaminergic neurons. Neuron 1994; 13: 1245-52
65. Kreiglestein K, Crazzolara CS, Fischer WH, et al. TGF-superfamily members promote survival of midbrain dopaminergic neurons and protect them against MPP+ toxicity. EMBO J 1995; 14: 736-42
66. Milbrandt J, de Sauvage FJ, Fahrner TJ, et al. Persephin, a novel neurotrophic factor related to GDNF and neurturin. Neuron 1998; 20: 245-53
67. Baloh RH, Tansey MG, Lampe PA, et al. Artemin, a novel member of the GDNF-ligand family, supports peripheral and central neurons and signals through the GFRalpha-3-RET receptor complex. Neuron 1998; 21: 1291-302
68. Lapchak PA, Jiao SS, Miller PJ, et al. Pharmacological characterization of glial cell line-derived neurotrophic factor: implications of GDNF as a therapeutic molecule to treat neurodegenerative diseases. Cell Tissue Res 1996; 286: 179-89
69. Woodbury D, Schaar D, Ramakrishnan L, et al. Novel structure of the human GDNF gene. Brain Res 1998: 803: 95-104
70. Rosenblad C, Kirik D, Devaux B, et al. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. Eur J Neurosci 1999; 11: 1554-66
71. Bilak MM, Shifrin DA, Corse AM, et al. Neuroprotective utility and neurotrophic action of nurturing in postnatal motor neurons: comparison with GDNF and Persephin. Mol Cell Neurosci 1999; 13: 326-36
72. Corse AM, Bilak MM, Bilak SR, et al. Preclinical testing of neuroprotective neurotrophic factors in a model of chronic motor neuron degeneration. Neurobiol Dis 1999; 6: 335-46
73. Airaksinen MS, Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 2002; 3: 383-94
74. Cacalano G, Fariñas I, Wang LC, et al. GFRalpha1 is an essential receptor component for GDNF in the developing nervous system and kidney. Neuron 1998; 21: 53-62
75. Heuckeroth RO, Enomoto H, Grider JR, et al. Gene targeting reveals a critical role for neurturin in the development and maintenance of enteric, sensory, and parasympathetic neurons. Neuron 1999; 22: 253-63
76. Klein RD, Sherman D, Ho WH, et al. A GPI-linked protein that interacts with Ret to form a candidate neurturin receptor. Nature 1997; 387: 717-21
77. Poteryaev D, Titievsky A, Sun YF, et al. GDNF triggers a novel ret-independent Src kinase family-coupled signaling via a GPI-linked GDNF receptor alpha1. FEBS Lett 1999; 463: 63-6
78. Trupp M, Scott R, Whittemore SR, et al. RET-dependent and -independent mechanisms of glial cell line-derived neurotrophic factor signaling in neuronal cells. J Biol Chem 1999; 274: 20885-94
79. Popsueva A, Poteryaev D, Arighi E, et al. GDNF promotes tubulogenesis of GFR1-expressing MDCK cells by Src-mediated phosphorylation of Met receptor tyrosine kinase. J Cell Biol 2003; 161: 119-29
80. Trupp M, Belluardo N, Funakoshi H, et al. Complementary and overlapping expression of glial cell line-derived neurotrophic factor (GDNF), c-ret proto-oncogene, and GDNF receptor-alpha indicates multiple mechanisms of trophic actons in the adult rat CNS. J Neurosci 1997; 17: 3554-67
81. Kokaia Z, Airaksinen MS, Nanobashvili A, et al. GDNF family ligands and receptors are differentially regulated after brain insults in the rat. Eur J Neurosci 1999; 11: 1202-16
82. Ylikoski J, Pirvola K, Virkkala J, et al. Guinea pig auditory neurons are protected by glial cell line-derived growth factor from degeneration after noise trauma. Hearing Res 1998; 124: 17-26
83. Paratcha G, Ledda F, Ibanez CF, et al. The neural cell adhesion molecule NCAM is an alternative signaling receptor for GDNF family ligands. Cell 2003; 113: 867-79
84. Salvatore MF, Zhang JL, Large DM. Striatal GDNF administration increases tyrosine hydroxylase phosphorylation in the rat striatum and substantia nigra. J Neurochem 2004; 90: 245-54
85. Gill SS, Patel NK, Hotton GR, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003; 9: 589-95
86. Bar KJ, Saldanha GJ, Kennedy AJ, et al. GDNF and its receptor component Ret in injured human nerves and dorsal root ganglia. Neuroreport 1998; 9: 43-7
87. Cho JW, Yarygina TO, Frances T, et al. Glial cell line-derived neurotrophic factor receptor GFRα1 is expressed in the rat striatum during postnatal development. Mol Brain Res 2004; 127: 96-104
88. Choi-Lundberg DL, Bohn MC. Ontogeny and distribution of glial cell line-derived neurotrophic factor (GDNF) mRNA in rat. Dev Brain Res 1995; 85: 80-8
89. Springer JE, Mu X, Bergman LW, et al. Expression of GDNF mRNA in rat and human nervous tissue. Exp Neurol 1994; 127: 167-70
90. Lenhard T, Suter-Crazzolara C. Developmental expression of GDNF, neurturin and their receptors in rat hippocampus. Neuroreport 1998; 9: 2927-31
91. Ikeda T, Xia XY, Ikenoue T. Expression of glial cell line-derived neurotrophic factor in the brain and cerebrospinal fluid of the developing rat. Int J Dev Neurosci 1999; 17: 681-91
92. Serra MP, Quartu M, Lai ML, et al. Expression of glial cell line-derived neurotrophic factor mRNA in the human newborn and adult hippocampal formation. Brain Res 2002; 928: 160-4
93. Ip NY, Yancopoulos GD. Ciliary neurotrophic factor and its receptor complex. Prog Growth Factor Res 1992; 4: 139-55
94. Akira S. IL-6 regulated transcription factors. Int J Biochem Cell Biol 1997; 29: 1401-18
95. Murphy M, Dutton R, Koblar S, et al. Cytokines which signal through the LIF receptor and their actions in the nervous system. Prog Neurobiol 1997; 52: 355-78
96. Nakashima K, Wiese S, Yanagisawa M, et al. Developmental requirement of gp130 signaling in neuronal survival and astrocyte differentiation. J Neurosci 1999; 19: 5429-34
97. Horton AR, Barlett PF, Pennica D, et al. Cytokines promote the survival of mouse cranial sensory neurons at different developmental stages. Eur J Neurosci 1998; 10: 673-9
98. Hudgins SN, Levison SW. Ciliary neurotrophic factor stimulates astroglial hypertrophy in vivo and in vitro. Exp Neurol 1998; 150: 171-82
99. Lee DA, Gross L, Wittrock DA, et al. Localization and expression of ciliary neurotrophic factor (CNTF) in postmortem sciatic nerve from patients with motor neuron disease and diabetic neuropathy. J Neuropathol Exp Neurol 1996; 55: 915-23
100. Adler R, Landa KB, Manthorpe M, et al. Cholinergic neuronotrophic factors: intraocular distribution of trophic activity for ciliary neurons. Science 1979; 204: 1434-6
101. Barbin G, Manthorpe M, Varon S. Purification of the chick eye ciliary neuronotrophic factor. J Neurochem 1984; 43: 1468-78
102. Manthorpe M, Skaper SD, Williams LR, et al. Purification of adult rat sciatic nerve ciliary neuronotrophic factor. Brain Res 1986; 367: 282-6
103. Lin LF, Mismer D, Lile JD, et al. Purification, cloning, and expression of ciliary neurotrophic factor (CNTF). Science 1989; 246: 1023-5
104. Stöckli KA, Lottspeich F, Sendtner M, et al. Molecular cloning, expression and regional distribution of rat ciliary neurotrophic factor. Nature 1989; 342: 920-3
105. Kunugi H, Hattori M, Ueki A, et al. Possible association of missense mutation (Gly[-63]Glu) of the neurotrophin-3 gene with Alzheimer's disease in Japanese. Neurosci Lett 1998; 241: 65-7
106. Ip NY, Yancopoulos GD. The neurotrophins and CNTF: two families of collaborative neurotrophic factors. Annu Rev Neurosci 1996; 19: 491-515
107. Curtis R, Adryan KM, Zhu Y, et al. Retrograde axonal transport of ciliary neurotrophic factor is increased by peripheral nerve injury. Nature 1993; 365: 253-5
108. Watanabe D, Yoshimura R, Khalil M, et al. Characteristic localization of gp130 (the signal-transducing receptor component used in common for IL-6/IL-11/CNTF/LIF/OSM) in the rat brain. Eur J Neurosci 1996; 8: 1630-40
109. Kordower JH, Yaping-Chu M, Maclennan AJ. Ciliary neurotrophic factor receptor alpha-immunoreactivity in the monkey central nervous system. J Comp Neurol 1997; 377: 365-80
110. Walker DG, Terai K, Mutsuo A, et al. Immunohistochemical analyses of fibroblast growth factor receptor-1 in the human substantia nigra: comparison between normal and Parkinson's disease cases. Brain Res 1998; 794: 181-7
111. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16: 3-34
112. Nakae J, Kido Y, Accili D. Distinct and overlapping functions of insulin and IGF-1 receptors. Endocr Rev 2001; 22: 818-35
113. De Meyts P, Whittaker J. Structural biology of insulin and IGF-I receptors: implications for drug design. Nature Rev Drug Discov 2002; 1: 769-83
114. Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endo Rev 1994; 15: 80-101
115. de Pablo F, de la Rosa EJ. The developing CNS: a scenario for the action of proinsulin, insulin and insulin-like growth factors. Trends Neurosci 1995; 18: 143-50
116. Doré S, Kar S, Quirion R. Rediscovering an old friend, IGF-I: potential use in the treatment of neurodegenerative diseases. Trends Neurosci 1997; 20: 326-31
117. Doré S, Kar S, Rowe W, et al. Distribution and levels of [125I]IGF-I, [125I]IGF-II and [125I] insulin receptor binding sites in the hippocampus of aged memory-unimpaired and -impaired rats. Neuroscience 1997; 80: 1033-40
118. Connor B, Beilharz EJ, Williams C, et al. Insulin-like growth factor-I (IGF-I) immunoreactivity in the Alzheimer's disease temporal cortex and hippocampus. Brain Res Mol Brain Res 1997; 49: 283-90
119. D'Ercole AJ, Ye P, Calikoglu AS, et al. The role of insulin-like growth factors in the central nervous system. Mol Neurobiol 1996; 13: 227-55
120. Folli F, Bonfanti L, Renard E, et al. Insulin receptor substrate-1 (IRS-1) distribution in the rat central nervous system. J Neurosci 1994; 14: 6412-22
121. Ye P, Umayahara Y, Ritter D, et al. Regulation of insulin-like growth factor I (IGF-I) gene expression in brain of transgenic mice expressing an IGF-I-luciferase fusion gene. Endocrinology 1997; 138: 5466-75
122. De Keyser J, Wilczak N, De Backer JP, et al. Insulin-like growth factor-I receptors in human brain and pituitary gland: an autoradiographic study. Synapse 1994; 3: 196-202
123. Duffy KR, Pardridge WM, Rosenfeld RG. Human blood-brain barrier insulin-like growth factor receptor. Metabolism 1988; 37: 136-40
124. Frank HJ, Pardridge WM, Morris WL, et al. Binding and internalization of insulin and insulin-like growth factors by isolated brain microvessels. Diabetes 1986; 35: 654-61
125. Hashimoto Y, Abiru Y, Nishio C, et al. Synergistic effects of brain-derived neurotrophic factor and ciliary neurotrophic factor on cultured basal forebrain cholinergic neurons from postnatal 2-week-old rats. Brain Res Dev Brain Res 1999; 115: 25-32
126. Panni MK, Atkinson J, Sofroniew MV. Leukemia inhibitory factor prevents loss of p75-nerve growth factor receptor immunoreactivity in medial septal neurons following fimbria-fornix lesions. Neuroscience 1999; 89: 1113-21
127. Loh NK, Woerly S, Bunt SM, et al. The regrowth of axons within tissue defects in the CNS is promoted by implanted hydrogel matrices that contain BDNF and CNTF producing fibroblasts. Exp Neurol 2001; 170: 72-84
128. Kossman T, Hans V, Imhof HG, et al. Interleukin-6 released in human cerebrospinal fluid following traumatic brain injury may trigger nerve growth factor production in astrocytes. Brain Res 1996; 713: 143-52
129. Giehl KM, Schutte A, Mestres P, et al. The survival promoting effect of glial cell line-derived neurotrophic factor on axotomized corticospinal neurons in vivo is mediated by an endogenous brain-derived neurotrophic factor mechanism. J Neurosci 1998; 18: 7351-60
130. Moore MW, Klein RD, Farinas I, et al. Renal and neuronal abnormalities in mice lacking GDNF. Nature 1996; 382: 76-9
131. Erickson JT, Brosenitsch TA, Katz DM. Brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor are required simultaneously for survival of dopaminergic primary sensory neurons in vivo. J Neurosci 2001; 21: 581-9
132. Zhou L, Shine HD. Neurotrophic factors expressed in both cortex and spinal cord induce axonal plasticity after spinal cord injury. J Neurosci Res 2003; 74: 221-6
133. Feng L, Wangl CY, Jiangl H, et al. Differential signaling of glial cell line-derived neurothrophic factor and brain-derived neurotrophic factor in cultured ventral mesencephalic neurons. Neuroscience 1999; 93: 265-73
134. Lang AE, Lozano AM. Parkinson's disease: first of two parts. N Engl J Med 1998; 339: 1044-53
135. Bennett DA, Beckett LA, Murray AM, et al. Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 1996; 334: 71-6
136. Morens DAM, Davis JW, Grandinetti A, et al. Epidemiologic observations on Parkinson's disease: incidence and mortality in a prospective study of middle-aged men. Neurology 1996; 46: 1044-50
137. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003; 39: 889-909
138. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991; 114: 2283-301
139. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease: pathophysiologic and clinical implications. N Engl J Med 1988; 318: 876-80
140. Gai WP, Blessing WW, Blumbergs PC. Ubiquitin-positive degenerating neuntes in the brainstem in Parkinson's disease. Brain 1995; 118: 1447-59
141. Braak H, Braak E, Yilmazer D, et al. Amygdala pathology in Parkinson's disease. Acta Neuropathol 1994; 88: 493-500
142. Tandberg E, Larsen JP, Aarsland D, et al. The occurrence of depression in Parkinson's disease: a community-based study. Arch Neurol 1996; 53: 175-9
143. Burke RE. Programmed cell death and Parkinson's disease. Mov Disortl 1998; 13 Suppl. 1: 17-23
144. Kösel S, Egensperger R, von Eitzen U, et al. On the question of apoptosis in the parkinsonian substantia nigra. Acta Neuropathol 1997; 93: 105-8
145. Lorigados L, Pavon N, Serrano T, et al. Nerve growth factor and neurological diseases. Rev Neurol 1998; 26: 744-8
146. Mogi M, Harada M, Kondo T, et al. Interleukin-1-beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from Parkinsonian patients. Neurosci Lett 1994; 180: 147-50
147. Howells DW, Porritt MJ, Wong JY, et al. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra. Exp Neurol 2000; 166: 127-35
148. Benisty S, Boissiere F, Faucheux B, et al. TrkB messenger RNA expression in normal human brain and in the substantia nigra of parkinsonian patients: an in situ hybridization study. Neuroscience 1998; 86: 813-26
149. Parain K, Murer MG, Yan Q, et al. Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra. Neuroreport 1999; 10: 557-61
150. Lin LFH, Doherty DH, Lile JD, et al. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993; 260: 1130-2
151. Beck KD, Valverde J, Alexi T, et al. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature 1995; 373: 339-41
152. Tomac A, Lindqvist E, Lin LF, et al. Protection and repair of dopaminergic system by GDNF in vivo. Nature 1995; 373: 335-9
153. Gash DM, Zhang Z, Ovadia A, et al. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 1996; 380: 252-5
154. Choi-Lundberg DL, Lin Q, Chang YN, et al. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 1997; 275: 838-41
155. Hunot S, Bernard V, Fauchex B. Glial cell-line derived neurotrophic factor (GDNF) gene expression in the human brain: a postmortem in situ hybridization study with special reference to Parkinson's disease. J Neural Transm 1996; 103: 1043-52
156. Schaar DG, Sieber BA, Sherwood AC, et al. Multiple astrocyte transcripts encode nigral trophic factors in rat and human. Exp Neurol 1994; 130: 387-93
157. Trupp M, Arenas E, Fainzilber M, et al. Functional receptor for GDNF encoded by the c-ret proto-oncogene. Nature 1996; 381: 785-8
158. Bozzi Y, Borrelli E. Absence of the dopamine D2 receptor leads to a decreased expression of GDNF and NT-4 mRNAs in restricted brain areas. Eur J Neurosci 1999; 11: 1275-84
159. Bessler H, Djaldetti R, Salman H, et al. IL-1 beta, IL-2. IL-6 and TNF-alpha production by peripheral blood mononuclear cells from patients with Parkinson's disease. Biomed Pharmacother 1999; 53: 141-5
160. Dobbs BJ, Charlett A, Purkiss AG, et al. Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism. Acta Neurol Scand 1999; 100: 34-41
161. Muller T, Blum-Degen D, Przuntek H, et al. Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease. Acta Neurol Scand 1998; 98: 142-4
162. Nagatsu T, Mogi M, Ichinose H, et al. Changes in cytokines and neurotrophins in Parkinson's disease. J Neural Transm Suppl 2000; 60: 277-90
163. Nagatsu T, Mogi M, Ichinose H, et al. Cytokines in Parkinson's disease. J Neural Transm Suppl 2000; 58: 143-51
164. Cardenas H, Bolin LM. Compromised reactive microgliosis in MPTP-lesioned IL-6 KO mice. Brain Res 2003; 985: 89-97
165. Cadet P, Zhu W, Mantione K, et al. Cyclic exercise induces anti-inflammatory signal molecule increases in the plasma of Parkinson's patients. Int J Mol Med 2003; 12: 485-92
166. Smith DE, Roberts J, Gage FH, et al. Age-associated neuronal atrophy occurs in the prinnte brain and is reversible by growth factor gene therapy. Proc Natl Acad Sci USA 1999; 96: 10893-8
167. Gibbs RB. Impairment of basal forebrain cholinergic neurons associated with aging and long-term loss of ovarian function. Exp Neurol 1998; 151: 289-302
168. Goldman SA. Adult neurogenesis: from canaries to the clinic. J Neurobiol 1998; 36: 267-86
169. Petersen RC, editor. Mild cognitive impairment: aging to alzheimer's disease. New York: Oxford University Press. 2003
170. Burns A. Mild cognitive impairment in older people. Lancet 2002; 360: 1963-5
171. Mufson EJ, Ma SY, Cochran EJ, et al. Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease. J Comp Neurol 2000; 427: 19-30
172. Mufson EJ, Ikonomovic MD, Styren SD, et al. Preservation of brain nerve growth factor in mild cognitive impairment and Alzheimer disease. Arch Neurol 2003; 60: 1143-8
173. Grossberg GT, Desai AK. Management of Alzheimer's disease. J Gerontol A Biol Sci Med Sci 2003; 58: 331-53
174. American Psychiatric Association, editor. Diagnostic and statistical manual of mental disorders. 4th ed. DSM-IV. Washington, DC: American Psychiatric Association, 1994
175. Kawas CH. Early Alzheimer's disease. N Engl J Med 2003; 349: 1056-63
176. Greene JD, Baddeley AD, Hodges JR. Analysis of the episodic memory deficit in early Alzheimer's disease: evidence from the doors and people test. Neuropsychologia 1996; 34; 537-51
177. Pillon B, Deweer B, Agid Y, et al. Explicit memory in Alzheimer's, Huntington's, and Parkinson's diseases. Arch Neurol 1993; 50: 374-9
178. Price BH, Gurvit H, Weintraub S, et al. Neuropsychological patterns and language deficits in 20 consecutive cases of autopsy-confirmed Alzheimer's disease. Arch Neurol 1993; 50: 931-7
179. Esteban-Santillan C, Praditsuwan R, Ueda H, et al. Clock drawing lest in very mild Alzheimer's disease. J Am Geriatr Soc 1998; 46: 1266-9
180. Kirk A, Kertesz A. On drawing impairment in Alzheimer's disease. Arch Neurol 1991; 48: 73-7
181. Wartiovaara K, Hytonen M, Vuori M, et al. Mutation analysis of the glial cell line-derived neurotrophic factor gene in Parkinson's disease. Exp Neurol 1998; 152: 307-9
182. Mega MS, Cummings JL, Fiorello T, et al. The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996; 46: 130-5
183. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-6
184. Williams LR, Varon S, Peterson GM, et al. Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transection. Proc Natl Acad Sci U S A 1986; 83: 9231-5
185. Haroutunian V, Kanof PD, Davis KL. Partial reversal of lesion-induced deficits in cortical cholinergic markers by nerve growth factor. Brain Res 1986; 386: 397-9
186. Hefti F. Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transections. J Neurosci 1986; 6: 2155-62
187. Kromer LF. Nerve growth factor treatment after brain injury prevents neuronal death. Science 1987; 235: 214-6
188. Gage FH, Armstrong DM, Williams LR, et al. Morphological response of axotomized septal neurons to nerve growth factor. J Comp Neurol 1988; 269: 147-55
189. Crutcher KA, Scott SA, Liang S, et al. Detection of NGF-like activity in human brain tissue: increased levels in Alzheimer's disease. J Neurosci 1993; 6: 2540-50
190. Scott SA, Mufson EJ, Weingartner JA, et al. Nerve growth factor in Alzheimer's disease: increased levels throughout the brain coupled with declines in nucleus basalis. J Neurosci 1995; 15: 6213-21
191. Hellweg R, Gericke CA, Jendroska K, et al. NGF content in the cerebral cortex of non-demented patients with amyloid plaques and in symptomatic Alzheimer's disease. Int J Dev Neurosci 1998; 16: 787-94
192. Hock C, Heese K, Hulette C, et al. Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch Neurol 2000; 57: 846-51
193. Peng S, Wuu J, Mufson EJ, et al. Increased proNGF levels in subjects with mild cognitive impairment and mild Alzheimer disease. J Neuropathol Exp Neurol 2004; 63: 641-9
194. Murase K, Nabeshima T, Robilaille Y, et al. NGF level of is not decreased in the serum, brain-spinal fluid, hippocampus, or parietal cortex of individuals with Alzheimer's disease. Biochem Biophys Res Commun 1993; 193: 198-203
195. Hock C, Heese K, Muller-Spahn F, et al. Decreased trkA neurotrophin receptor expression in the parietal cortex of patients with Alzheimer's disease. Neurosci Lett 1998; 241: 151-4
196. Narisawa-Saito M, Wakabayashi K, Tsuji S, et al. Regional specificity of alterations in NGF, BDNF and NT-3 levels in Alzheimer's disease. Neuroreport 1996; 7: 2925-8
197. Goedert M, Fine A, Dawbarn D, et al. Nerve growth factor receptor: mRNA distribution in human brain. Normal levels in basal forebrain in Alzheimer's disease. Mol Brain Res 1989; 5: 1-7
198. Jette N, Cole MS, Fahnestock M. NGF mRNA is not decreased in frontal cortex from Alzheimer's disease patients. Mol Brain Res 1994; 25: 242-50
199. Fahnestock M, Scott SA, Jette N, et al. Nerve growth factor mRNA and protein levels measured in the same tissue from normal and Alzheimer's disease parietal cortex. Mol Brain Res 1996; 42: 175-8
200. Mufson EJ, Li JM, Sobreviela T, et al. Decreased trkA gene expression within basal forebrain neurons in Alzheimer's disease. Neuroreport 1996; 8: 25-9
201. Mufson EJ, Lavine N, Jaffar S, et al. Reduction in p140-TrkA receptor protein within the nucleus basalis and cortex in Alzheimer's disease. Exp Neurol 1997; 146: 91-103
202. Marinelli L, Cammarata S, Nobbio L, et al. Tyrosine kinase A-nerve growth factor receptor is antigenically present in dystrophic neuntes from a variety of conditions but not in Alzheimer's disease. Neurosci Lett 1999; 273: 67-71
203. Boissiere F, Faucheux B, Ruberg M, et al. Decreased TrkA gene expression in cholinergic neurons of the striatum and basal forebrain of patients with Alzheimer's disease. Exp Neurol 1997; 1451: 245-52
204. Salehi A, Ocampo M, Verhaagen J, et al. p75 neurotrophin receptor in the nucleus basalis of Meynert in relation to age, sex and Alzheimer's disease. Exp Neurol 2000; 161: 245-58
205. Boissiere F, Faucheuxl B, Agid Y, et al. Expression of catalytic trkB gene in the striatum and the basal forebrain of patients with Alzheimer's disease: an in situ hybridization study. Neurosci Lett 1997; 221: 141-4
206. Salehi A, Verhaagen J, Dijkhuizen PA, et al. Co-localization of high-affinity neurotrophin receptors in nucleus basalis of Meynert neurons and their differential reduction in Alzheimer's disease. Neuroscience 1996; 75: 373-87
207. Phillips HS, Jeanne M, Armanini M, et al. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron 1991; 7: 695-702
208. Amoureux MC, Van Cool D, Herrero MT, et al. Regulation of metallothionein-III (GIF) mRNA in the brain of patients with Alzheimer's disease is not impaired. Mol Chem Neuropathol 1997; 32: 101-21
209. Ferrer I, Marin C, Rey MJ, et al. BDNF and full-length and truncated TrkB expression in Alzheimer's disease: implications in therapeutic strategies. J Neuropathol Exp Neurol 1999; 58: 729-39
210. Conner JM, Lauterborn JC, Van Q, et al. Distribution of brain-derived neurotrophic factor (BDNF) protein and mRNA in the normal adult rat CNS: evidence for anterograde axonal transport. J Neurosci 1997; 17: 2295-313
211. Goodman LJ, Valverde J, Lim F, et al. Regulated release and polarized localization of brain-derived neurolrophic factor in hippocampal neurons. Molec cell Neurosci 1996; 7: 222-38
212. Allen SJ, Wilcox GK, Dawbarn D. Profound and selective loss of catalytic TrkB immunoreactivity in Alzheimer's disease. Biochem Biophys Res Comm 1999; 264: 648-51
213. Birecree E, Whetsell WO, Stoscheck Jr C, et al. Immunoreactive epidermal growth factor receptors in neuritic plaques from patients with Alzheimer's disease. J Neuropath Exp Neurol 1988; 47: 549-60
214. Eikelenboom P, Zhan SS, Kamphorst W, et al. Cellular and substrate adhesion molecules (integrins) and their ligands in cerebral amyloid deposits in Alzheimer's disease. Virchows Arch 1994; 424: 421-7
215. Gomez-Pinilla F, Cummings BJ, Cotman CW. Induction of basic fibroblast growth factor in Alzheimer's disease and pathology. NeuroReport 1990; 1: 211-4
216. Terry RD, Masliah E, Hansen LA. Structural basis of the cognitive alterations in Alzheimer's disease. In: Terry RD, Katzman R, Bick KL, editors. Alzheimer's disease. New York: Raven. 1994: 179-96
217. Nance MA. Huntington disease: clinical, genetic, and social aspects. J Geriatr Psychiatry Neurol 1998; 11: 61-70
218. Orr H. Beyond the Qs in the polyglutamine diseases. Genes Dev 2001; 15: 925-32
219. Gusella JF, Persichetti F, MacDonald ME. The genetic defect causing Huntington's disease: repeated in other contexts? Mol Med 1997; 3: 238-46
220. Martin JB. Pathogenesis of neurodegenerative disorders: the role of dynamic mutations. Neuroreport 1996; 8: i-vii
221. MacDonald ME, Barnes G, Srinidhi J, et al. Gametic but not somatic instability of CAG repeat length in Huntington's disease. J Med Genet 1993; 30: 982-6
222. Myers RH, MacDonald ME, Koroshetz WJ, et al. De novo expansion of a (CAG)n repeal in 'sporadic' Huntington's disease. Nat Genet 1993; 5: 168-73
223. Durr A, Dode C, Hahn V, et al. Diagnosis of sporadic Huntington's disease. J Neurol Sci 1995; 129: 51-5
224. Martin JB. Molecular basis of the neurodegenerative disorders. N Engl J Med 1999; 340: 1970-80
225. Young AB. Huntington's disease and other trinucleotide repeat disorders. In: Martin JB, editor. Molecular neurology. New York: Scientific American, 1998: 35-54
226. Zuccato A, Ciammola D, Rigamonti BR, et al. Loss of Huntington-mediated BDNF gene transcription in Huntington's disease. Science 2001; 293: 493-8
227. Brown RH. Amyotrophic lateral sclerosis and the inherited motor neuron diseases. In: Martin JB, editor. Molecular neurology. New York: Scientific American, 1998: 223-38
228. Mulder DW, Kurland LT, Offord KP, et al. Familial adult motor neuron disease: amyotrophic lateral sclerosis. Neurology 1986; 36: 511-7
229. Leigh PN, Anderton BH, Dodson A, et al. Ubiquitin deposits in anterior horn cells in motor neurone disease. Neurosci Lett 1988; 93: 197-203
230. Mezey E, Dehejia A, Harta G, et al. Alpha synuclein in neurodegenerative disorders: murderer or accomplice? Nat Med 1998; 4: 755-7
231. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362: 59-62
232. Robberecht W. Genetics of amyotrophic lateral sclerosis. J Neurol 2000; 247: 2-6
233. Stuerenburg HJ, Kunze K. Tissue nerve growth factor concentrations in neuromuscular diseases. Eur J Neurol 1998; 5: 487-90
234. Kust BM, Copray JC, Brouwer N, et al. Elevated levels of neurotrophins in human biceps brachii tissue of amyotrophic lateral sclerosis. Exp Neurol 2002; 177: 419-27
235. Mutoh T, Sobue G, Hamano T, et al. Decreased phosphorylation levels of TrkB neurotrophin receptor in the spinal cords from patients with amyotrophic lateral sclerosis. Neurochem Res 2000; 25: 239-45
236. Nishio T, Sunohara N, Furukawa S. Neurotrophin switching in spinal moloneurons of amyotropic lateral sclerosis. Neuroreport 1998; 9: 1661-5
237. Grundstrom E, Lindholm D, Johansson A, et al. GDNF but not BDNF is increased in cerebrospinal fluid in amyotrophic lateral sclerosis. Neuroreport 2000; 11: 1781-3
238. Grundstrom E, Askmark H, Lindeberg J, et al. Increased expression of glial cell line-derived neurotrophic factor mRNA in muscle biopsies from patients with amyotrophic lateral sclerosis. J Neurol Sci 1999; 162: 169-73
239. Mitsuma N, Yamamoto M, Li M, et al. Expression of GDNF receptor (RET and GDNFR-alpha) mRNAs in the spinal cord of patients with amyotrophic lateral sclerosis. Brain Res 1999; 820: 77-85
240. Nutt JG, Burchiel KJ, Comella CL, et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD: implanted intracerebroventricular glial cell line-derived neurotrophic factor study group. Neurology 2003; 60: 69-73
241. Olson L, Nordberg A, von Holst H, et al. Nerve growth factor affects 11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient [case report]. J Neural Transm Park Dis Dement Sect 1992; 4: 79-95
242. Eriksdotter Jonhagen M, Nordberg A, Amberla K, et al. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord 1998; 9: 246-57
243. Tuszynski MH, Jolla La, Thai L, et al. Phase I trial of nerve growth factor ex vivo gene therapy for Alzheimer's disease [abstract S17.002]. 56th Annual Meeting of the American Academy of Neurology; 2004 Apr 24-May 1: San Francisco
244. Bradley WG. A phase I/II study of recombinant brain-derived neurotrophic in patients with ALS. Ann Neurol 1995; 38: 971
245. The BDNF Study Group Phase III. A controlled trial of recombinant methionyl human BDNF in ALS. Neurology 1999; 52: 1427-33
246. Ochs G, Penn RD, York M, et al. A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 201-6
247. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis: ALS CNTF Treatment Study Group. Neurology 1996; 46 (5): 1244-9
248. Miller RG, Bryan WW, Dietz MA, et al. Toxicity and tolerability of recombinant human ciliary neurotrophic factor in patients with amyotrophic lateral sclerosis. Neurology 1996; 47: 1329-31
249. Miller RG, Petajan JH, Bryan WW, et al. A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis: rhCNTF ALS study group. Ann Neurol 1996; 39: 256-60
250. Aebischer P, Schluep M, Deglon N, et al. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat Med 1996; 6: 696-9
251. Lai EC, Felice KJ, Festoff BW, et al. Effect of recombinant human insulin-like growth factor-1 on progression of ALS: a placebo-controlled study. Neurology 1997; 49: 1621-30
252. Borasio GD, Robberecht W, Leigh PN, et al. A placebo controlled trial of insulin-like nerve growth factor-1 in amyotrophic lateral sclerosis. Neurology 1998; 51: 583-6
253. Spenger C, Hyman C, Studer L, et al. Effects of BDNF on dopaminergic, serotonergic, and GABAergic neurons in cultures of human fetal ventral mesencephalon. Exp Neurol 1995; 133: 50-63
254. Hoglinger GU, Sautter J, Meyer M, et al. Rat fetal ventral mesencephalon grown as solid tissue cultures: influence of culture time and BDNF treatment on dopamine neuron survival and function. Brain Res 1998; 813: 313-22
255. Lapchak P, Beck K, Raujo D, et al. Chronic intranigral administration of brain-derived neurotrophic factor produces striatal dopaminergic hypofunction in unlesioned adult rats and fails to attenuate the decline of striatal dopaminergic function following medial forebrain bundle transection. Neuroscience 1993; 53: 183-34
256. Altar CA, Boylan CB, Fritsche M, et al. The neurotrophins NT-4/5 and BDNF augment serotonin. dopamine, and GABAergic systems during behaviorally effective infusions to the substantia nigra. Exp Neurol 1994; 30: 31-40
257. Yurek DM, Lu W, Hipkens S, et al. BDNF enhances the functional reinnervation of (he striatum by grafted fetal dopamine neurons. Exp Neurol 1996; 137: 105-18
258. Yoshimato Y, Lin Q, Collier TJ, et al. Astrocytes retrovirally transduced with BDNF elicit behavioral improvement in a rat model of Parkinson's disease. Brain Res 1995; 691: 25-36
259. Levivier M, Przedborski S, Bencsics C, et al. Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease. J Neurosci 1995; 15: 7810-20
260. Volpe BT, Wildmann J, Altar CA. Brain-derived neurotrophic factor prevents the loss of nigral neurons induced by excitotoxic striatal/pallidial lesions. Neuroscience 1998; 83: 741-8
261. Klein RL, Muir D, King MA, et al. Long-term actions of vector-derived nerve growth factor or brain-derived neurotrophic factor on choline acetyltransferase and Trk receptor levels in the adult rat basal forebrain. Neuroscience 1999; 90: 815-21
262. Wang ZH, Ji Y, Shan W, et al. Therapeutic effects of astrocytes expressing both tyrosine hydroxylase and brain-derived neurotrophic factor on a rat model of Parkinson's disease. Neuroscience 2002; 113: 629-40
263. Widmer HR, Schaller B, Meyer M, et al. Glial cell line-derived neurotrophic factor stimulates the morphological differentiation of cultured ventral mesencephalic calbindin- and calretinin-expressing neurons. Exp Neurol 2000; 164: 71-81
264. Meyer M, Matarredona ER, Seiler RW, et al. Additive effect of glial cell line-derived neurotrophic factor and neurotrophin-4/5 on rat fetal nigral explant cultures. Neuroscience 2001; 108: 273-84
265. Bjorklund A, Rosenbladl C, Winkler C, et al. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. Neurobiol Dis 1997; 4: 186-200
266. Gash DM, Gerhardt GA, Hoffer BJ. Effects of glial cell line-derived neurotrophic factor on the nigrostriatal dopamine system in rodents and nonhuman primates. Adv Pharmacol 1998; 42: 911-5
267. Lapchak PA, Miller PJ, Collins F, et al. Glial cell line-derived neurotrophic factor attenuates behavioural deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: comparison of intraventricular and intranigral delivery. Neuroscience 1997; 78: 61-72
268. Schneider JS, Peacock V. Differential effects of GDNF' treatment on rotational asymmetry, skilled forelimb use deficits and sensory neglect in unilateral 6-OHDA-lesioned rats. Restor Neurol Neurosci 1998; 13 (3-4): 205-12
269. Aoi M, Date I, Tomita S, et al. The effect of intrastriatal single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: behavioral and histological studies using two different dosages. Neurosci Res 2000; 36: 319-25
270. Kirik D, Georgievska B, Rosenblad C, et al. Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson. Eur J Neurosci 2001; 13 (8): 1589-99
271. Lindner MD, Winn SR, Baetge EE, et al. Implantation of encapsulated catecholamine and GDNF-producing cells in rats with unilateral dopamine depletions and parkinsonian symptoms. Exp Neurol 1995; 132: 62-76
272. Rosenblad C, Martinez-Serrano A, Bjorklund A. Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease. Neuroscience 1998; 82: 129-37
273. Georgievska B, Kirik D, Bjorklund A. Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer. Exp Neurol 2002; 177: 461-74
274. Tang FI, Tien LT, Zhou FC, et al. Intranigral ventral mesencephalic grafts and nigrostriatal injections of glial cell line-derived neurotrophic factor restore dopamine release in the striatum of 6-hydroxydopamine-lesioned rats. Exp Brain Res 1998; 119: 287-96
275. Mandel RJ, Snyder RO, Leff SE. Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease. Exp Neurol 1999; 160: 205-14
276. Rosenblad C, Gronborg M, Hansen C, et al. In vivo protection of nigral dopamine neurons by lentiviral gene transfer of the novel GDNF-family member neublastin/artemin. Mol Cell Neurosci 2000: 15: 199-214
277. Natsume A, Mata M, Goss J, et al. Bcl-2 and GDNF delivered by HSV-mediated gene transfer act additively to protect dopaminergic neurons from 6-OHDA-induced degeneration. Exp Neurol 2001; 169: 231-8
278. Ostenfeld T, Tai YT, Martin P, et al. Neurospheres modified to produce glial cell line-derived neurotrophic factor increase the survival of transplanted dopamine neurons. J Neurosci Res 2002; 69: 955-65
279. Chen X, Liu W, Guoyuan Y, et al. Protective effects of intracerebral adenoviral-mediated GDNF gene transfer in a rat model of Parkinson's disease. Parkinsonism Relat Disord 2003; 10: 1-7
280. Oiwa Y, Yoshimura R, Nakai K, et al. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease. Brain Res 2002; 947: 271-83
281. Horger BA, Nishimura MC, Armanini MP, et al. Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J Neurosci 1998; 18: 4929-37
282. Akerud P, Holm PC, Castelo-Branco G, et al. Persephin-overexpressing neural stem cells regulate the function of nigral dopaminergic neurons and prevent their degeneration in a model of Parkinson. Mol Cell Neurosci 2002; 21: 205-22
283. Frim DM, Uhler TA, Kern WR, et al. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenyl-pyridinium toxicity to dopaminergic neurons in the rat. Proc Natl Acad Sci U S A 1994; 91: 5104-8
284. Tsukahara T, Takeda M, Shimohama S, et al. Effects of brain-derived neurotrophic factor on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys. Neurosurgery 1995; 37: 733-9
285. Pearce RK, Costa S, Jenner P, et al. Chronic supranigral infusion of BDNF in normal and MPTP-treated common marmosets. J Neural Transm 1999; 106: 663-83
286. Inoue T, Tsui J, Wong N, et al. Expression of glial cell line-derived neurotrophic factor and its mRNA in the nigrostriatal pathway following MPTP treatment. Brain Res 1999; 826: 306-8
287. Miyoshi Y, Zhang Z, Ovadia A, et al. Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys. Ann Neurol 1997; 42: 208-14
288. Gerhardt GA, Cass WA, Huettl P, et al. GDNF improves dopamine function in the substantia nigra but not the putamen of unilateral MPTP-lesioned rhesus monkeys. Brain Res 1999; 817: 163-71
289. Costa S, Iravani MM, Pearce RK, et al. Glial cell line-derived neurotrophic factor concentration dependently improves disability and motor activity in MPTP-treated common marmosets. Eur J Pharmacol 2001; 412: 45-50
290. Kojima H, Abiru Y, Sakajiri K, et al. Adenovirus-mediated transduction with human glial cell line-derived neurotrophic factor gene prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopamine depletion in striatum of mouse brain. Biochem Biophys Res Commun 1997; 238: 569-73
291. Eberhardt O, Coelln RV, Kugler S, et al. Protection by synergistic effects of adenovirus-mediated X-chromosome-linked nhibitor of apoptosis and glial cell line-derived neurotrophic factor gene transfer in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Neurosci 2000; 20: 9126-34
292. Kordower JH, Emborg ME, Bloch J, et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000; 290: 767-73
293. Sautter J, Sable M, Sommer C, et al. BDNF and TrkB expression in intrastriatal ventral mesencephalic grafts in a rat model of Parkinson's disease. J Neural Transm 1998; 105: 253-63
294. Kordower JH, Palfi S, Chen EY, et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 1999; 46: 419-24
295. Gage FH, Wolff JA, Rosenberg MB, et al. Grafting genetically modified cells to the brain: possibilities for the future. Neuroscience 1987; 23: 795-807
296. Chen KS, Nishimura MC, Armanini MP, et al. Disruption of a single allele of the nerve growth factor gene results in atrophy of basal forebrain cholinergic neurons and memory deficits. J Neurosci 1997; 17: 7288-96
297. Capsoni S, Ugolini G, Comparini A, et al. Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice. Proc Natl Acad Sci U S A 2000; 97: 6826-31
298. Ruberti F, Capsoni S, Comparini A, et al. Phenotypic knockout of nerve growth factor in adult transgenic mice reveals severe deficits in basal forebrain cholinergic neurons, cell death in the spleen, and skeletal muscle dystrophy. J Neurosci 2000; 20: 2589-601
299. Capsoni S, Giannotta S, Cattaneo A. Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc Natl Acad Sci U S A 2002; 99: 12432-7
300. Fischer W, Wictorin K, Bjorklundl A, et al. Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature 1987; 329: 65-8
301. Koliatsos VE, Nauta HJ, Clatterbuck RE, et al. Mouse nerve growth factor prevents degeneration of axotomized basal forebrain cholinergic neurons in the monkeys. J Neurosci 1990; 10: 3801-13
302. Tuszynski MH, U HS, Amaral DG, et al. Nerve growth factor infusion in the primate brain reduces lesion-induced cholinergic neuronal degeneration. J Neurosci 1990; 10: 3604-14
303. Tuszynski MH, Sang H, Yoshida K, et al. Recombinant human nerve growth factor infusion prevents cholinergic neuronal degeneration in the adult primate brain. Ann Neurol 1991; 30: 625-36
304. Mandel RJ, Gage FH, Thal LJ. Spatial learning in rats: correlation with cortical choline acetyltransferase and improvement with NGF following NBM damage. Exp Neurol 1989; 104: 208-17
305. Will B, Hefti F. Behavioural and neurochemical effects of chronic intraventricular injections of nerve growth factor in adult rats with fimbria lesions. Behav Brain Res 1985; 17: 17-24
306. Fischer W, Bjorklund A. Loss of AChE- and NGFr-labeling precedes neuronal death of axotomized septal-diagonal band neurons: reversal by intraventricular NGF infusion. Exp Neurol 1991; 113: 93-108
307. Fischer W. Nerve growth factor reverses spatial memory impairments in aged rats. Neurochem Int 1994; 25: 47-52
308. Blesch A, Conner JM, Tuszynski MH. Modulation of neuronal survival and axonal growth in vivo by tetracycline-regulated neurotrophin expression. Gene Ther 2001; 8: 954-60
309. Altar CA, Bakhit C. Receptor-mediated transport of human recombinant nerve growth factor from olfactory bulb to forebrain cholinergic nuclei. Brain Res 1991; 541: 82-8
310. Chen XQ, Fawcett JR, Rahman YE, et al. Delivery of nerve growth factor to the brain via the olfactory pathway. J Alzheimers Dis 1998; 1: 35-44
311. Thorne RG, Frey WH. Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin Pharmacokinet 2001; 40: 907-46
312. Moller HJ. Reappraising neurotransmitter based strategies. Eur Neuropsychopharmacol 1999; 9 Suppl. 2: s53-59
313. Martinez-Serrano A, Bjorklund A. Immortalized neural progenitor cells for CNS gene transfer and repair. Trends Neurosci 1997; 20: 530-8
314. Perez-Navarro E, Canudas AM, Akerund P, et al. Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4/5 prevent the death of striatal projection neurons in a rodent model of Huntington's disease. J Neurochem 2000; 75: 2190-9
315. Perez-Navarro E, Alberch J, Neveu I, et al. Intrastriatal brain-derived neurotrophic factor, neurotrophin-3 and neurotrophin-4/5 differentially regulate the phenotype and prevent degenerative changes in striatal projection neurons after excilotoxicity in vivo. Neuroscience 1999; 91: 1257-64
316. Canals JM, Checa N, Marco S, et al. Expression of brain-derived neurotrophic factor in cortical neurons is regulated by striatal target area. J Neurosci 2001; 21: 117-24
317. Alberch J, Perez-Navarro E, Canals JM. Neuroprotection by neurotrophins and GDNF family members in the excitotoxic model of Huntington's disease. Brain Res Bull 2002; 57: 817-22
318. Haase G, Kennel P, Pettmann B, et al. Gene therapy of murine motor neuron disease using adenoviral vectors for neurotrophic factors. Nat Med 1997; 3: 429-36
319. Arakawa Y, Sendtner M, Thoenen H. Survival effect of ciliary neurotrophic factor (CNTF) on chick embryonic motoneurons in culture: comparison with other neurotrophic factors and cytokines. J Neurosci 1990; 10: 3507-15
320. Sjoberg J, Kanje M. Insulin-like growth factor (IGF-I) as a stimulator of regeneration in the freeze-injured rat sciatic nerve. Brain Res 1989; 485: 102-8
321. Near SL, Whalen LR, Miller JA, et al. Insulin-like growth factor II stimulates motor nerve regeneration. Proc Natl Acad Sci U S A 1992; 89: 11716-20
322. Contreras PC, Steffler C, Yu E, et al. Systemic administration of rhIGF-I enhanced regeneration after sciatic nerve crush. J Pharmacol Exp Ther 1995; 27: 1443-9
323. Ang LC, Bhaumick B, Munoz DG, et al. Effects of astrocytes insulin and insulin-like growth factor I on the survival of motoneurons in vitro. J Neurol Sci 1992; 109: 168-72
324. Gehrmann J, Yao DL, Bonetti B, et al. Expression of insulin-like growth factor-I and related peptides during motoneuron regeneration. Exp Neurol 1994; 128: 202-10
325. Cheng H-L, Randolph A, Yee D, et al. Characterization of insulin-like growth factor-I and its receptor binding proteins in transected nerves and cultured Schwann cells. J Neurochem 1996; 66: 525-36
326. Lewis ME, Neff NT, Contreras PC, et al. Insulin-like growth factor-1: potential for treatment of motor neuronal disorder. Exp Neurol 1993; 124: 73-88
327. Caroni P. Activity-sensitive signals by muscle-derived IGFs in the developing and regenerating neuromuscular system. Ann N Y Acad Sci 1993; 692: 209-22
328. Neff NT, Prevette D, Houenou LJ, et al. Insulin-like growth factors: putative muscle-derived trophic agents that promote motoneuron survival. J Neurobiol 1993; 24: 1558-66
329. Caroni P, Grandes P. Nerve sprouting in innervated adult skeletal muscle induced by elevated levels of insulin-like nerve growth factors. J Cell Biol 1990; 110: 1307-17
330. Adem A, Ekblom J, Gillberg P-G, et al. Insulin-like growth factor-I receptors in human spinal cord: changes in amyotrophic lateral sclerosis. J Neural Transm Gen Sect 1994; 97: 73-84
331. Torres-Aleman I, Barrios V, Berciano J. The peripheral insulin-like growth factor system in amyotrophic lateral sclerosis and in multiple sclerosis. Neurology 1998; 50: 772-6
332. Momose Y, Murata M, Kobayashi K, et al. Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms. Ann Neurol 2002; 51: 133-6
333. Hakansson A, Melke J, Westberg L, et al. Lack of association between the BDNF Val66Met polymorphism and Parkinson's disease in a Swedish population. Ann Neurol 2003; 53: 823
334. Kunugi H, Ueki A, Otsuka M, et al. A novel polymorphism of the brain-derived neurotrophic factor (BDNF) gene associated with late-onset Alzheimer's disease. Mol Psychiatry 2001; 6: 83-6
335. Ventriglia M, Benussi L, Bocchio Chiavetto L, et al. Association between the BDNF 196 A/G polymorphism and sporadic Alzheimer. Mol Psychiatry 2002; 7: 136-7
336. Riemenschneider M, Schwarz S, Wagenpfeil S, et al. A polymorphism of the brain-derived neurotrophic factor (BDNF) is associated with Alzheimer's disease in patients lacking the Apolipoprotein E epsilon4 allele. Mol Psychiatry 2002; 7: 782-5
337. Imura T, Shimohama S, Kawamata J, et al. Genetic variation in the ciliary neurotrophic factor receptor alpha gene and familial amyotrophic lateral sclerosis. Ann Neurol 1998; 43: 275
338. Giess R, Goetz R, Schrank B, et al. Potential implications of a ciliary neurolrophic factor gene mutation in a German population of patients with motor neuron disease. Muscle Nerve 1998; 21: 236-8
339. Ono S, Imai T, Igarashi A, et al. Decrease in the ciliary neurotrophic factor of the spinal cord in amyotrophic lateral sclerosis. Eur Neurol 1999; 42: 163-8
340. Saragovi HU, Gehring K. Development of pharmacological agents for targeting neurotrophins and their receptors. Trends Pharmacol Sci 2000; 21: 93-8
341. Davidsen BL, Breakefield XO. Viral vectors for gene delivery to the nervous system. Nat Rev Neurosci 2003; 4: 353-64
342. Alisky JM, Hughes SM, Sauter SL, et al. Transduction of murine cerebellar neurons with recombinant FIV and AAV5 vectors. Neuroreport 2000; 11: 2669-73
343. Menei P, Pean JM, Nerriere-Daguin V, et al. Intracerebral implantation of NGF-releasing biodegradable microspheres protects striatum against excitotoxic damage. Exp Neurol 2000; 161: 259-72
344. Pean JM, Menei P, Morel O, et al. Intraseptal implantation of NGF-releasing microspheres promotes the survival of axotomized cholinergic neurons. Biomaterials 2000; 21: 2097-101
345. Veziers J, Lesourd M, Jollivet C, et al. Analysis of brain biocompatibility of drug-releasing biodegradable microspheres by scanning and transmission electron microscopy. J Neurosurg 2001; 95: 489-94
346. Gouhier C, Chalon S, Aubert-Pouessel A, et al. Protection of dopaminergic nigrostriatal afferents by GDNF delivered by microspheres in a rodent model of Parkinson's disease. Synapse 2002; 44: 124-31
347. Jollivet C, Aubert-Pouessel A, Clavreul A, et al. Long-term effect of intra-striatal glial cell line-derived neurotrophic factor-releasing microspheres in a partial rat model of Parkinson's disease. Neurosci Lett 2004; 356: 207-10